Pharmacy

AbbVie completes $10.9 billion acquisition of Apogee Therapeutics

AbbVie’s $10.9 billion Apogee deal deepens its immunology bet

AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, gaining clinical-stage drugs for atopic dermatitis, asthma and other inflammatory diseases. The deal strengthens AbbVie’s immunology pipeline but is expected to dilute earnings until the next decade.

Sign up now for our monthly newsletter!

Gain access to the latest articles and sneak-peaks of upcoming releases by subscribing.